Literature DB >> 31669739

Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia.

Xiaojiong Jia1, Weijia Ma2, Jianchun He3, Xiaolang Tian4, Hang Liu5, Hua Zou5, Si Cheng6.   

Abstract

INTRODUCTION: Heteroresistance to antibiotic agents can lead to diagnostic and therapeutic failures; however, to date, cefepime heteroresistance (FEP-HR) in Pseudomonas aeruginosa (P. aeruginosa) bacteraemia has not been characterised. The primary goal of this study was to investigate the molecular epidemiology, mechanisms and risk factors for cefepime-heteroresistant P. aeruginosa bacteraemia over approximately 6 years in Southwest China.
RESULTS: A high prevalence (57.3%) of heteroresistance to cefepime was observed during the study period, and these FEP-HR isolates were not clonally related. Mechanistic studies revealed that AmpC hyperproduction contributed to the development of this phenomenon. In addition, patients with advanced age, haematological malignancies, central venous catheters, and previous cephalosporin therapy were identified as independent risk factors for acquiring FEP-HR P. aeruginosa bacteraemia. Furthermore, patients infected with FEP-HR were generally at a greater risk for an adverse prognosis compared with those with non-FEP-HR. More importantly, characterisation of three successive P. aeruginosa isolates recovered from the same patient revealed that heteroresistance can act as an intermediate stage during the evolution from susceptibility to full resistance in patients undergoing antibiotic therapy for prolonged periods.
CONCLUSION: These findings emphasised the necessity of antimicrobial stewardship programs in clinical settings, as well as the need for some rapid screening methods for detecting this phenomenon.
Copyright © 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Bacteraemia; Cefepime; Heteroresistance; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2020        PMID: 31669739     DOI: 10.1016/j.ijantimicag.2019.10.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.

Authors:  Damien Fournier; Romain Carrière; Maxime Bour; Emilie Grisot; Pauline Triponney; Cédric Muller; Jérôme Lemoine; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Heteroresistance to Amikacin in Carbapenem-Resistant Klebsiella pneumoniae Strains.

Authors:  Feiyang Zhang; Qin Li; Jiawei Bai; Manlin Ding; Xiangjin Yan; Guangxi Wang; Baoli Zhu; Yingshun Zhou
Journal:  Front Microbiol       Date:  2021-12-02       Impact factor: 5.640

3.  Characteristics of Helicobacter pylori Heteroresistance in Gastric Biopsies and Its Clinical Relevance.

Authors:  You-Hua Wang; Xiao-Ling Gong; Ding-Wei Liu; Rong Zeng; Lin-Fu Zhou; Xiao-Yan Sun; Dong-Sheng Liu; Yong Xie
Journal:  Front Cell Infect Microbiol       Date:  2022-02-04       Impact factor: 5.293

Review 4.  Relationships between Efflux Pumps and Emergence of Heteroresistance: A Comprehensive Study on the Current Findings.

Authors:  Mohammad Abavisani; Mansoor Kodori; Fariba Akrami; Ali Radfar; Ali Hashemi
Journal:  Can J Infect Dis Med Microbiol       Date:  2022-09-19       Impact factor: 2.585

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.